Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial.
Brad H RovinRichard A FurieJorge A Ross TerresSophia GiangThomas SchindlerArmando TurchettaJay P GargWilliam F PendergraftAna MalvarPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Post hoc analyses of NOBILITY demonstrated that compared with standard-of-care therapy, obinutuzumab treatment resulted in superior preservation of kidney function and prevention of LN flares. More patients achieved CRR at week 76 with less glucocorticoid use in the obinutuzumab group.